Recent news on Intron A

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),Psychiatric adverse events, which include insomnia, were common (57 percent) with PEGINTRON but similar to INTRON A (58 percent). Depression was most common

Pharmaceutical drugmakers slammed for marketing practices  -  May 11, 2007
Blogging Stocks...to the government about drug prices and illegally promoted the drugs Temodar and Intron A for the treatment of cancers for which they were not approved.

Biotechs and the generic drug market  -  May 10, 2007
Ars Technica,Drugs such as Epogen and Intron A are derived from cultured cells and then purified. This approach to developing drugs has been quite successful for

Companies marketing drugs for 'off-label' use  -  May 10, 2007
Miami Herald,...it lied to the government about drug prices and illegally promoted Temodar and Intron A for the treatment of certain cancers without approval.

Illegal drug marketing pays off  -  May 10, 2007
News-Leader.com,...to the government about drug prices and illegally promoted drugs Temodar and Intron A for the treatment of cancers for which they were not approved.

Schering-Plough Sued in NJ for Marketing Drugs for Off-Label Uses  -  Apr 23, 2007
Law.com (subscription),The drugs at the center of the litigation are Intron A and Temador. Intron A, approved to treat hepatitis, has been prescribed for such off-label uses as

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),In addition, the company offers ongoing educational programs in China to help support patients on PEGINTRON and INTRON A therapy.

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 11, 2007
PharmaLive.com (press release),Psychiatric adverse events, which include insomnia, were common (57 percent) with PEGINTRON but similar to INTRON A (58 percent). Depression was most common

Fresh from the Pipeline: Telbivudine  -  Apr 5, 2007
Nature.com (subscription),A recombinant form of interferon-- 2b (Intron A; Schering–Plough) became the first FDA-approved drug for treating HBV in 1992. It has the advantages of a

Metabolic Research, Inc. Appoints Dr. Robert Shorr as Chairman of ...  -  Mar 29, 2007
Genetic Engineering News (press release),Previously, he has served as Vice President Science and Technology at Enzon Inc., where he worked with Schering Plough to develop PEG INTRON A. Dr Shorr was

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),160 28% TEMODAR 196 163 20% AVELOX 115 80 43% CLARITIN RX 112 101 11% INTEGRILIN 84 80 6% REBETOL 71 78 (8%) CAELYX 62 51 21% INTRON A 60 60 - SUBUTEX

New investor-backed clinics seek profits on demand for cancer care  -  Mar 21, 2007
Kyiv Post,Production of generic copies of top world drugs, such as Intron A, Roferon, Actimune, Enbrel, as well as the company’s own developed medicines,

New Hampshire : Pharmaceutical Manufacturer Schering-Plough Pays ...  -  Feb 27, 2007
All American Patriots (press release),...a medication used to treat brain tumors, and that it paid improper inducements to promote the prescribing of Intron-A, a bladder cancer treatment,

Bruning Announces $1.8 Million Medicaid Fraud Settlement  -  Feb 9, 2007
Southwest Nebraska News,Schering allegedly paid kickbacks to doctors to induce them to prescribe hepatitis drugs PEG-Intron and Rebetron and bladder cancer medication Intron-A,

Louisiana Settles with Schering-Plough  -  Feb 10, 2007
All American Patriots (press release),...and bladder cancer medication Intron-A. Resulting losses to state Medicaid Programs were in excess of $80 million which, under the terms of the national

AG says Vermont received $725000 drug settlement  -  Feb 5, 2007
Legal News Line,...and K-Dur, and for partaking in illegal business practices with the drugs Temodar and Intron A. Schering-Plough was alleged to have offered kickbacks to

Schering-Plough Reports Financial Results for 2006 Fourth Quarter ...  -  Jan 29, 2007
PR Newswire (press release),356 371 (4%) INTEGRILIN 85 71 20% 329 315 5% REBETOL 75 94 (21%) 311 331 (6%) AVELOX 103 68 51% 304 228 34% INTRON A 57 66 (14%) 237 287 (17%) CAELYX 49

Vermont : Schering-Plough Pays $435 Million For Improper Marketing ...  -  Feb 6, 2007
All American Patriots (press release),The illegal marketing concerns the drugs Temodar, used in the treatment of brain tumors and metastases, and Intron A, used in the treatment of superficial

Maryland : Maryland Attorney General Gansler Announces $1 Million ...  -  Feb 7, 2007
All American Patriots (press release),The settlement also resolves allegations that Schering made illegal payments to physicians to induce them to use its cancer drugs Temodar and Intron A for

Schering is fined $435M by feds  -  18 Jan 2007
Worcester Telegram,The company also promoted the unapproved use of Intron A for the treatment of cancer on the surface of the bladder, prosecutors said.

Business notebook  -  18 Jan 2007
Boston Globe,...s guilty plea for making false statements to government agencies about its brain-tumor treatment Temodar, its bladder cancer drug Intron A, and other

Academics create a cheaper Hep C drug  -  Jan 2, 2007
Ars Technica,The drug in question is PEG-intron, a protein based drug that is based on a family of cytokines. Unlike other interferon-based therapies,

Drug Gives Kidney Cancer Patients Longer Lives  -  Jan 11, 2007
Ivanhoe,...(Sutent) extends survival and increases quality of life when used as a front line treatment better than the widely used drug interferon alfa (Intron A).

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional